Aptose Biosciences Inc. APTO
Set alert
At close · Feb 10
52-week range unavailable
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 1.71
- Prev close
- 1.71
- Mkt cap
- 14.88M
- Vol
- 648.21K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.71
- High
- 1.71
- Forward P/E
- -0.11
- Beta
- 0.00
- Short ratio
- 0.12
- Inst. own
- 16.68%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.2968
- 200-d avg
- 0.71675
- 1y target
- 2.00
News
4 months ago globenewswire.com
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML 32 AML patients dosed across 40 mg, 80 mg, 120 mg and…
5 months ago globenewswire.com
Aptose Reports First Quarter 2026 Results
SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a…
7 months ago defenseworld.net
Aptose Biosciences (TSE:APS) Stock Passes Above 50-Day Moving Average – Time to Sell?
Aptose Biosciences Inc. (TSE: APS - Get Free Report) (NASDAQ: APTO)'s share price passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of C$2.21 and…
9 months ago defenseworld.net
Aptose Biosciences (TSE:APS) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?
Aptose Biosciences Inc. (TSE: APS - Get Free Report) (NASDAQ: APTO)'s stock price crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of C$2.19 and…
10 months ago globenewswire.com
Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
Aptose's Tuspetinib Triple Drug Therapy Featured at 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Population
11 months ago defenseworld.net
Aptose Biosciences (TSE:APS) Shares Pass Above Fifty Day Moving Average – Should You Sell?
Aptose Biosciences Inc. (TSE: APS - Get Free Report) (NASDAQ: APTO) crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of C$1.89 and traded…
1 year ago globenewswire.com
Aptose Announces Auditor Not Standing for Re-Appointment
SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS)…
1 year ago globenewswire.com
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS)…
1 year ago benzinga.com
Dow Dips Over 400 Points; ISM Manufacturing PMI Falls In March
Dow Dips Over 400 Points; ISM Manufacturing PMI Falls In March
1 year ago globenewswire.com
Aptose Reports Year End 2024 Results and Corporate Highlights
Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt…
1 year ago globenewswire.com
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the…
1 year ago benzinga.com
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday?
On Thursday, Aptose Biosciences Inc. APTO announced that the Cohort Safety Review Committee monitoring Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax…
1 year ago globenewswire.com
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
Aptose Announces Positive Clinical Safety Review and Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib
1 year ago benzinga.com
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
1 year ago globenewswire.com
Aptose Announces Reverse Share Split
SAN DIEGO and TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the…
1 year ago benzinga.com
US Stocks Likely To Open Higher Amid Ukraine Peace Talk Hopes As Russian, American Officials Meet
U.S. stock futures rose on Tuesday following a mixed close on Friday after the Presidents' Day holiday on Monday.
1 year ago benzinga.com
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket
1 year ago globenewswire.com
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
SAN DIEGO and TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the…
1 year ago globenewswire.com
Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AML TUS+VEN+AZA triplet achieves Cycle 1 complete remissions in FLT3-wildtype AML patients TUS+VEN+AZA triplet shows…
1 year ago globenewswire.com
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced…
1 year ago globenewswire.com
Aptose Announces Positive Decision by Nasdaq Hearings Panel
SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly…
1 year ago globenewswire.com
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells
1 year ago globenewswire.com
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. Sites TUS and TUS+VEN Broadly Active Across AML Populations, with Favorable Safety TUS-based therapies are…
1 year ago globenewswire.com
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
-
1 year ago benzinga.com
Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
-
2 years ago benzinga.com
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 647 companies set new 52-week lows.
-
3 years ago benzinga.com
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Wednesday saw 59 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 129 stocks made new 52-week lows.
-
3 years ago benzinga.com
Earnings Scheduled For May 8, 2023
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.
-
3 years ago benzinga.com
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.
-
4 years ago benzinga.com
Earnings Scheduled For November 1, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 120 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Thursday saw 177 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 78 companies made new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 1076 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 507 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 191 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 422 stocks made new 52-week lows.
-
4 years ago benzinga.com
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
-
4 years ago benzinga.com
32 Stocks Moving in Wednesday's Pre-Market Session
Gainers Zentek Ltd. (NASDAQ: ZTEK) rose 180.5% to $7.63 in pre-market trading after declining around 5% on Tuesday.
-
4 years ago benzinga.com
Earnings Scheduled For March 22, 2022
Companies Reporting Before The Bell • GDS Holdings (NASDAQ:GDS) is projected to report quarterly loss at $0.18 per share on revenue of $338.69 million.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 729 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 524 stocks hit new 52-week lows.